Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). - Wikidata - awgldk - TriplyDB

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

http://www.wikidata.org/entity/Q33370672

about

Breast cancer brain metastases: the last frontier Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.Current approaches to the treatment of metastatic brain tumours.Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.Treatment of Breast Cancer Brain Metastases.Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells Chemotherapy and targeted molecular therapies for brain metastases.Mechanisms and insights into drug resistance in cancer S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy.Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.Breast cancer brain metastases: new directions in systemic therapy CNS metastasis in primary breast cancer.Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair.Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.Brain metastasis: new opportunities to tackle therapeutic resistance.Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro.Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

P2860

Q26775663-FA0E6E55-A0FA-4094-B1F5-B43785C2000C Q28072442-346BADDC-83E9-43F1-858A-5ACAA0EADFC1 Q28477059-47A607BC-CA40-486E-AE01-119A7B414AEA Q33386298-DF515BED-5C03-4274-BBAE-0D21EBFD0EC4 Q33696559-A7BD0295-882C-4EB0-95E0-A30B594F443A Q33909294-8B0C815F-0177-43C1-83E8-36EE8C887B88 Q34372972-2A1F6188-1194-4FA2-9EA7-196BD074B8DB Q34571940-F910FFAC-10AE-4BEA-A327-A0F001EEC828 Q34634616-A369A9EA-3541-400A-A01B-D567C51BD4D2 Q35600833-D533489C-F354-429E-91E1-732FF596D3FC Q35914677-07681D58-3835-4B4E-B49F-5418B8B05607 Q36057858-08DBEE94-5069-4DC4-95C7-225832770265 Q36214603-B0EE897A-602E-4D1C-9F3F-C5938F1DB044 Q36641504-5779F53D-51F4-4643-8D26-C9A5A1DC14B1 Q36682301-F7279921-5C3D-4BAC-9075-F8E76C14B6AE Q36734940-94784310-B1DB-42B9-9873-BBCDB4EBF254 Q36820588-84AD6D97-2B98-4BF9-906A-F8AFA2F30F22 Q36822500-04911308-57D1-4DD8-8975-736EA1845424 Q37004668-F7186C6F-B554-4A59-A78C-E8B12D61591A Q37188627-391FB3A9-7420-47BF-8974-692C69DF2C75 Q37284300-169C4D9C-B427-4A4E-841F-B919FB672FE0 Q37430234-194F913F-481A-489C-A569-76A3F0346A14 Q37698300-C97AAAF1-27B9-4398-8268-F3D06D57A9A5 Q37870216-DA141C6B-A781-4921-803F-AD441B2DAE49 Q38064719-25FCEE7B-1ED8-4E9A-90A1-8D6BEA5D1414 Q38222247-FED9E17E-9890-479F-881C-D3BEEFC0119D Q38230553-CAD0AC09-8D45-4A99-9B10-044BC294C566 Q38792519-21EC9563-E8BD-447D-86A0-1ED52CBF5AD7 Q38811820-C656CE0F-57B4-45C1-AC88-36A9224513C8 Q48401767-C5075F8C-9D54-4308-8E46-597EF670AAE9 Q48471112-5F2B9D1B-A3F4-43D9-AB5C-6293309A13C4 Q51565735-9F4CC0EB-5F50-442F-A10E-F07CCB30038F Q54207869-84AAF75C-B5FF-4B2A-8B78-A0C676928456 Q55309832-4EEFEA4F-01E4-4B28-B9E8-E625DD789EF8

P2860

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

http://www.wikidata.org/entity/Q33370672

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@ast

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@en

type

label

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@ast

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@en

prefLabel

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@ast

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@en

P1433

Q33370672-B25FE591-EAC5-4120-9A91-233765E8E509

P1476

Q33370672-E357D21B-B2CB-49C2-AE18-5D9CCE7333C7

P2093

Q33370672-21D3E0B5-2EF1-49D2-82C4-13C90B7D69E0

Q33370672-401EF923-2040-4425-B1BE-89222BE2D86F

Q33370672-4CC02DCA-C4F4-4653-9DE3-0BA2D625A812

Q33370672-9275FDE8-300D-429D-8693-8CF6C83819C6

Q33370672-CA7EF662-88AE-438C-849F-05B6FAF7CC8F

Q33370672-DC6C3FB9-9B0B-48E8-A9B3-F1AE016D2634

Q33370672-E77CEF0B-1E86-4282-88D2-BE7468380F17

P2860

Q33370672-0B34A14A-82EF-460E-8C1F-CAC466BCABE6

Q33370672-0EFD740D-2BDF-48BB-90A7-C51ED4BC1877

Q33370672-12D5C783-3446-4E5D-A493-22BF2F9190F0

Q33370672-16AF1193-3720-4A36-A057-BC08D5BAE754

Q33370672-3CE3ACBF-9867-4653-946C-B89DB9909DA6

Q33370672-62693F69-0F0C-42B3-A1D1-9BC1F4DDBD7E

Q33370672-7A47383D-9E6E-4AD3-A769-25AC2F488B6A

Q33370672-8EEFF149-0F10-4A97-9C19-D3F3C566A5D3

Q33370672-9D7C5148-6736-4CDA-A5DD-8139B367B6FE

Q33370672-A6133B22-3799-4C1B-A6A6-A1EEBBE838BC

P304

Q33370672-5C486E7C-8802-48C1-BA7E-51BB64E43224

P31

Q33370672-A90710BC-EC67-4EA8-A3C5-7D6634081CA4

P356

Q33370672-BDFBDEB3-458F-42DA-9D19-BACE9737D428

P433

Q33370672-75E86AA9-CA21-4295-AF94-367E0E373413

P478

Q33370672-33814019-782A-474E-BE60-BA86896CEDDA

P577

Q33370672-2D6FDCFF-3557-4CD7-87CB-521730606A08

P5875

Q33370672-D1E40C2D-4D38-4A46-B997-4D312459F9C6

P698

Q33370672-20ECF421-8010-4FA1-8503-8074F7341C64

P921

Q33370672-06DEC26A-DBCA-4A77-BDF8-5B0FB262519C

Q33370672-47B3834D-7120-496D-A2DC-ED5EF9028C74

P356

P1433

Annals of Oncology

P1476

Temozolomide in metastatic bre ...... nical Trials Group (NCIC-CTG).

@en

P2093

D Charpentier

http://www.w3.org/2001/XMLSchema#string

E Eisenhauer

http://www.w3.org/2001/XMLSchema#string

L Bordeleau

http://www.w3.org/2001/XMLSchema#string

L Yelle

http://www.w3.org/2001/XMLSchema#string

M Crump

http://www.w3.org/2001/XMLSchema#string

M E Trudeau

http://www.w3.org/2001/XMLSchema#string

S Matthews

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.

Oral alkylating agents for breast cancer therapy.

MGMT: its role in cancer aetiology and cancer therapeutics.

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

P304

952-956

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDL056

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7214451

http://www.w3.org/2001/XMLSchema#string

P698

16565212

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial